Pfizer recalls EpiPens after devices fail to activate
-
Share on Facebook
-
Share on Twitter
- Copy Link
Pfizer Canada has issued a recall for specific lots of their EpiPen and EpiPen Jr. auto-injectors.
The auto-injectors deliver an emergency dose of adrenaline to patients who are suffering from anaphylaxis as a result of an allergic reaction. The recall was issued after two confirmed international reports of the devices failing to activate, but noted no such cases had been reported in Canada.
The products impacted by the recall are EpiPen (0.3 mg epinephrine) auto-injector lot 5Gu763 marked with the expiry date May, 2017 and EpiPen Jr. (0.15 mg epinephrine) auto-injector lot 5GR765, with expiry dates of March, 2017. More than 100,000 units of the recalled injectors have been distributed in Canada.
Anyone in possession of one of the recalled devices is advised to contact their pharmacy to arrange for a return and replacement as soon as possible. More information on the recall is available through the Government of Canada website.
